Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project.


Journal

Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086

Informations de publication

Date de publication:
05 2020
Historique:
received: 22 10 2018
accepted: 26 03 2019
pubmed: 23 5 2019
medline: 21 7 2020
entrez: 23 5 2019
Statut: ppublish

Résumé

The California Lupus Surveillance Project (CLSP) is a population-based registry of individuals with systemic lupus erythematosus (SLE) residing in San Francisco County, California from 2007 to 2009, with a special focus on Asian/Pacific Islander and Hispanic patients. We used retrospective CLSP data to analyze racial and ethnic differences in lupus manifestations and in the timing and risk of developing severe manifestations. A total of 724 patients with SLE were retrospectively identified. Prevalence ratios (PRs) of SLE manifestations were calculated using Poisson regression models stratified by race/ethnicity and adjusted for sex, age at SLE diagnosis, and disease duration. We studied onset of severe SLE manifestations after SLE diagnosis using Kaplan-Meier methods to examine time-to-event and Cox proportional hazards regression models to estimate hazard ratios (HRs). White patients were the referent group in all analyses. African Americans, Asian/Pacific Islanders, and Hispanic patients had increased prevalence of renal manifestations (PR 1.74 [95% confidence interval (95% CI) 1.40-2.16], PR 1.68 [95% CI 1.38-2.05], and PR 1.35 [95% CI 1.05-1.74], respectively). Furthermore, African Americans had increased prevalence of neurologic manifestations (PR 1.49 [95% CI 1.12-1.98]), and both African Americans (PR 1.09 [95% CI 1.04-1.15]) and Asian/Pacific Islanders (PR 1.07 [95% CI 1.01-1.13]) had increased prevalence of hematologic manifestations. African Americans, Asian/Pacific Islanders, and Hispanic patients, respectively, had higher risk of developing lupus nephritis (HR 2.4 [95% CI 1.6-3.8], HR 4.3 [95% CI 2.9-6.4], and HR 2.3 [95% CI 1.4-3.8]) and thrombocytopenia (HR 2.3 [95% CI 1.1-4.4], HR 2.3 [95% CI 1.3-4.2], and HR 2.2 [95% CI 1.1-4.7]). Asian/Pacific Islander and Hispanic patients had higher risk of developing antiphospholipid syndrome (HR 2.5 [95% CI 1.4-4.4] and HR 2.6 [95% CI 1.3-5.1], respectively). This is the first epidemiologic study comparing lupus manifestations among 4 major racial and ethnic groups. We found substantial differences in the prevalence of several clinical SLE manifestations among racial/ethnic groups and discovered that African Americans, Asian/Pacific Islanders, and Hispanic patients are at increased risk of developing several severe manifestations following a diagnosis of SLE.

Identifiants

pubmed: 31115180
doi: 10.1002/acr.23887
pmc: PMC6872905
mid: NIHMS1020586
doi:

Types de publication

Comparative Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

622-629

Subventions

Organisme : NIAMS NIH HHS
ID : K24 AR074534
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP006486
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR070155
Pays : United States
Organisme : NCCDPHP CDC HHS
ID : U01 DP005120
Pays : United States
Organisme : ACL HHS
ID : U01DP005120
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019, American College of Rheumatology.

Références

J Am Soc Nephrol. 2007 Jan;18(1):244-54
pubmed: 17167111
Arthritis Rheum. 2001 Dec;44(12):2797-806
pubmed: 11762940
Lupus. 2010 Feb;19(2):119-29
pubmed: 19946032
Arthritis Rheumatol. 2014 Feb;66(2):369-78
pubmed: 24504809
Curr Rheumatol Rep. 2003 Oct;5(5):391-4
pubmed: 12967526
Arthritis Rheumatol. 2014 Feb;66(2):357-68
pubmed: 24504808
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
Semin Arthritis Rheum. 1989 Feb;18(3):189-97
pubmed: 2648578
J Clin Rheumatol. 2001 Jun;7(3):142-50
pubmed: 17039119
Kidney Int. 2006 May;69(10):1846-51
pubmed: 16598205
J Clin Invest. 1996 Mar 1;97(5):1348-54
pubmed: 8636449
Arthritis Rheum. 1998 Jul;41(7):1161-72
pubmed: 9663471
Medicine (Baltimore). 2004 Jan;83(1):1-17
pubmed: 14747764
Am J Med. 2002 Jun 15;112(9):726-9
pubmed: 12079714
Lupus. 2006;15(1):26-31
pubmed: 16482742
Arthritis Rheumatol. 2017 Oct;69(10):1996-2005
pubmed: 28891237
PLoS One. 2018 Jun 28;13(6):e0199003
pubmed: 29953444
J Rheumatol. 2012 Apr;39(4):759-69
pubmed: 22382348
Arthritis Rheumatol. 2017 Oct;69(10):2006-2017
pubmed: 28891252
Arthritis Rheum. 1990 Jan;33(1):37-48
pubmed: 2302266
J Rheumatol. 1990 Feb;17(2):220-4
pubmed: 2319521
Curr Rheumatol Rep. 2004 Dec;6(6):458-62
pubmed: 15527705
Lupus. 2016 Oct;25(11):1217-23
pubmed: 26921269
Lupus. 2011 May;20(6):561-7
pubmed: 21415256
Arthritis Rheumatol. 2014 Sep;66(9):2494-502
pubmed: 24891315

Auteurs

Ernest Maningding (E)

University of California, San Francisco.

Maria Dall'Era (M)

University of California, San Francisco.

Laura Trupin (L)

University of California, San Francisco.

Louise B Murphy (LB)

Centers for Disease Control and Prevention, Atlanta, Georgia, GE.

Jinoos Yazdany (J)

University of California, San Francisco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH